BofA warns Fed risks policy mistake with early rate cuts
Investing.com -- AtriCure , Inc. (NASDAQ:ATRC), a provider of surgical treatments for atrial fibrillation and related conditions, reported second quarter earnings that exceeded analyst expectations and raised its full-year outlook, sending shares surging 15% in trading.
The company posted a second quarter loss of -$0.13 per share, beating analyst estimates of -$0.17 per share. Revenue jumped 17.1% YoY to $136.1 million, surpassing the consensus estimate of $130.17 million. The strong performance was driven by growing adoption across the company’s product portfolio, particularly its AtriClip platform and cryoSPHERE devices.
U.S. revenue increased 15.7% to $110.6 million, while international revenue grew 23.3% to $25.6 million. The company’s adjusted EBITDA reached $15.4 million, up significantly from the same period last year.
"Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio," said Michael Carrel, President and CEO at AtriCure. "We’re seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes."
Following the strong quarter, AtriCure raised its full-year 2025 guidance, now projecting revenue between $527 million and $533 million, above the previous analyst consensus of $523 million. The company also improved its full-year adjusted loss per share forecast to between -$0.39 and -$0.34, better than analysts’ expectations of -$0.51.
Gross profit for the quarter was $101.5 million with a gross margin of 74.5%, representing a slight decrease of 15 basis points from the second quarter of 2024 due to less favorable geographic and product mix.
The company now expects to generate modest positive cash flow for the full year 2025, further strengthening its financial position as it continues to expand its product offerings for atrial fibrillation, left atrial appendage management, and post-operative pain management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.